Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.758 USD | -2.58% | +20.70% | -12.87% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company appears to be poorly valued given its net asset value.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.87% | 320M | C | ||
+16.42% | 124B | B+ | ||
+19.02% | 112B | B+ | ||
+3.52% | 22.94B | B | ||
-11.63% | 17.02B | B | ||
-16.50% | 16.88B | A- | ||
-39.57% | 16.87B | A- | ||
+2.68% | 13.63B | C+ | ||
+21.16% | 11.61B | C+ | ||
+108.78% | 10.31B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMRN Stock
- Ratings Amarin Corporation plc